International
The Morning Science

What science found today

‹
 

Research

[Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?

The Lancet · By Gilles Edan & Emmanuelle Le Page ·

The Brief

  • A Lancet comment asks whether remibrutinib, a BTK inhibitor, can be a high-efficacy disease-modifying drug for relapsing multiple sclerosis.
  • BTK inhibitors directly modulate B lymphocytes and myeloid cells, including macrophages and microglia.
  • Because they act on both adaptive and innate immune mechanisms, BTK inhibitors target two sides of MS immunopathology.

Why it matters

It reports on a possible new drug approach for relapsing multiple sclerosis, and science readers can track whether its mechanism translates into clinical efficacy.

Who’s affected

  • people with relapsing multiple sclerosis
  • neurologists and clinical MS researchers

Bruton's tyrosine kinase (BTK) inhibitors directly modulate the functions of B lymphocytes and myeloid cells (notably macrophages and microglia) and thus target both the adaptive and innate mechanisms that contribute to the immunopathology of multiple sclerosis on either side of…

Timeline

  1. Lancet comment on remibrutinib for relapsing multiple sclerosis published

  2. thelancet.com

    [Comment] Remibrutinib: a high-efficacy disease-modifying drug for relapsing multiple sclerosis?

How do you feel about this?

0 Comments